Passage Bio, Inc.
PASG
$8.49
$0.465.73%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -25.96% | -17.92% | -15.46% | -17.48% | -13.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -32.10% | -29.18% | -28.45% | -28.93% | -27.31% |
| Operating Income | 32.10% | 29.18% | 28.45% | 28.93% | 27.31% |
| Income Before Tax | 34.21% | 25.75% | 24.84% | 36.54% | 38.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 34.21% | 25.75% | 24.84% | 36.54% | 38.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.21% | 25.75% | 24.84% | 36.54% | 38.78% |
| EBIT | 32.10% | 29.18% | 28.45% | 28.93% | 27.31% |
| EBITDA | 30.77% | 28.45% | 28.37% | 29.43% | 27.71% |
| EPS Basic | 37.82% | 32.73% | 33.77% | 42.94% | 43.38% |
| Normalized Basic EPS | 36.97% | 36.56% | 37.98% | 37.10% | 34.05% |
| EPS Diluted | 37.82% | 32.73% | 33.77% | 42.98% | 43.42% |
| Normalized Diluted EPS | 36.97% | 36.56% | 37.98% | 37.10% | 34.05% |
| Average Basic Shares Outstanding | 5.89% | 9.38% | 13.19% | 11.40% | 8.36% |
| Average Diluted Shares Outstanding | 5.89% | 9.38% | 13.19% | 11.40% | 8.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |